Ventavis (iloprost) / Bayer, J&J, University of Copenhagen - LARVOL DELTA

PROSTASICKLE: Evaluation of the Efficacy of Iloprost in the Management of Vaso-occlusive Crises in Adult Patients With Sickle Cell Disease (clinicaltrials.gov) - P3 | N=144 | Not yet recruiting | Sponsor: University Hospital, Rouen

New P3 trial • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Iloprost-loaded inhalable Nano into Micro (NiM) formulations for treating hyper-inflammation in a pre-clinical model of cystic fibrosis airway epithelial cells. (PubMed, Drug Deliv Transl Res) - "Cytofluorimetry analysis carried out by using NiM samples entrapping fluorescent pegylated and unpegylated nanoparticles loaded with ILO showed that both nanoparticles NiM formulations were internalized by cells in a concentration-dependent manner. Our results demonstrate that inhalable NiM-based formulations delivery system loaded with ILO can efficiently attenuate inflammation in a pre-clinical model of human airway epithelium."

Journal • Preclinical • Cystic Fibrosis • Genetic Disorders • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CXCL8 • IL1B • IL6 • MIR145 • MIR146A • MIR17 • TNFA

REFRACTORY DIGITAL ULCERS AND CHRONIC OSTEOMYELITIS COMPLICATING DIFFUSE SYSTEMIC SCLEROSIS: A REAL-LIFE CASE (SSWC 2026) - "Digital ulcers were refractory to nifedipine 60 mg/day, prompting escalation to alprostadil in 2013 and iloprost in 2016, both initially effective...Sildenafil (up to 150 mg/day, 2024–2025) proved ineffective. Bosentan, initiated in January 2025, was discontinued after re-hospitalization in August 2025 for multiple ulcers and chronic osteomyelitis of the right fifth digit...Osteomyelitis developed in the right second digit in 2019, requiring multiple antibiotic courses (flucloxacillin, amoxicillin–clavula- nate, clindamycin, trimethoprim–sulfamethoxazole) following Staphylococcus aureus isolation, with relapse in 2020 managed with ciprofloxacin...Mycophenolate mofetil (2017–2019) was used for progressive skin fibrosis and NSIP but discontinued due to recurrent osteomyeli- tis. Nintedanib (2021–2024) was initiated for progressive pulmonary fibrosis but withdrawn due to severe diarrhea and weight loss... This case illustrates the complex therapeutic challenges in SSc..."

Clinical • Cardiovascular • Fibrosis • Hepatology • Hypotension • Immunology • Infectious Disease • Inflammation • Interstitial Lung Disease • Musculoskeletal Diseases • Orthopedics • Pneumonia • Primary Biliary Cholangitis • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis • Venous Ulcer

Efficacy, safety and tolerability of home-based iloprost administration for acral vascular manifestations in Scleroderma patients: a single-centre real life study (EULAR 2026) - No abstract available

Clinical • Immunology • Scleroderma • Systemic Sclerosis

AirFly: Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost (clinicaltrials.gov) - P=N/A | N=50 | Not yet recruiting | Sponsor: University of Sao Paulo General Hospital

New trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

MANAGING PREGNANCY IN A PATIENT WITH UNREPAIRED TRUNCUS ARTERIOSUS AND PULMONARY HYPERTENSION (ACC 2026) - "She was on sildenafil, bosentan, and full-dose enoxaparin for thromboembolism prevention...Decision-Making: As pregnancy continued, sildenafil was continued, bosentan stopped, and oxygen, iloprost, and aspirin added... Pregnancy is contraindicated in pulmonary arterial hypertension due to Truncus Arteriosus. The European and American Society of Cardiology advise termination of pregnancy during the first trimester. If continued, management should focus on O₂ >90% and preventing thrombotic events."

Clinical • Cardiovascular • Heart Failure • Hematological Disorders • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

CARDIOPULMONARY REHABILITATION IN SEVERE CONGENITAL HEART DISEASE: INSIGHTS FROM A YOUNG PATIENT WITH EISENMENGER SYNDROME (ACC 2026) - "Case: A 27-year-old male with perimembranous ventricular septal defect (VSD) and Eisenmenger physiology, on triple pulmonary vasodilator therapy (sildenafil, bosentan, and iloprost), presented with New York Heart Association (NYHA) class II/III dyspnea. Despite significant ventilatory and perfusion inefficiencies, structured rehabilitation improved key prognostic markers. This case highlights the feasibility and clinical benefit of exercise training in adults with Eisenmenger syndrome."

Clinical • Cardiovascular • Heart Failure • Pulmonary Disease

Frostbite in Children: A Case Series and Development of a New Iloprost-Driven Protocol: Les engelures chez les enfants : une série de cas et l'élaboration d'un nouveau protocole faisant appel à l'iloprost. (PubMed, Plast Surg (Oakv)) - "Key elements of the new Frostbite Management in Children Protocol include rewarming, iloprost infusion, alteplase administration, and hyperbaric oxygen therapy, if required. An iloprost-based protocol has been developed for children with frostbite. The protocol was accepted by hospital staff and well tolerated by the patients."

Journal • Immunology

TRAVEL DISTANCE TO TERTIARY HEALTHCARE REFLECTS DISEASE SEVERITY AND MEDICATION ACCESS IN SYSTEMIC SCLEROSIS PATIENTS: INSIGHTS FROM THE ITALIAN SPRING REGISTRY OF THE ITALIAN SOCIETY OF RHEUMATOLOGY (SSWC 2026) - "Similarly, access to multiple immunosuppressants (cyclophosphamide, azathioprine, methotrexate, tocilizumab) and vasoactive/vasodilator drugs (Endothelin Receptor Antagonists (ERA), Phosphodieste- rase Type 5 Inhibitors (PDE5i), iloprost) was associated with increased probability of long travel distances (Table 1). SSc patients with pulmonary complications are more likely to undertake longer commuting distances and have a higher likelihood of receiving advanced treatments. Public health strategies should aim to enhance accessibility to specialized care and advanced therapies for these patients, recognizing the impact of travel burden on healthcare access."

Clinical • Cardiovascular • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

METABOLIC AND CLINICAL CORRELATES OF INSULIN RESISTANCE IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL MONOCENTRIC STUDY (SSWC 2026) - "Medications such as corticosteroids, hydroxychloroquine, statins, and Iloprost were more frequently used in the IR group (Table 4). In SSc, IR is associated with metabolic dysregulation, more severe disease phenotype and specific autoantibodies profile. These findings suggest a potential link between metabolic and fibrotic pathways."

Clinical • Dyslipidemia • Fibrosis • Immunology • Interstitial Lung Disease • Metabolic Disorders • Musculoskeletal Diseases • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

TRAVEL DISTANCE TO TERTIARY HEALTHCARE REFLECTS DISEASE SEVERITY AND MEDICATION ACCESS IN SYSTEMIC SCLEROSIS PATIENTS: INSIGHTS FROM THE ITALIAN SPRING REGISTRY OF THE ITALIAN SOCIETY OF RHEUMATOLOGY (SSWC 2026) - "Similarly, access to multiple immunosuppressants (cyclophosphamide, azathioprine, methotrexate, tocilizumab) and vasoactive/vasodilator drugs (Endothelin Receptor Antagonists (ERA), Phosphodieste- rase Type 5 Inhibitors (PDE5i), iloprost) was associated with increased probability of long travel distances (Table 1). SSc patients with pulmonary complications are more likely to undertake longer commuting distances and have a higher likelihood of receiving advanced treatments. Public health strategies should aim to enhance accessibility to specialized care and advanced therapies for these patients, recognizing the impact of travel burden on healthcare access."

Clinical • Cardiovascular • Immunology • Interstitial Lung Disease • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

2020/0421/HP: Evaluation of the efficacy of iloprost in the management of vaso-occlusive crises in adult patients with sickle cell: a multicentre, randomised, double-blind, placebo-controlled study _ PROSTASICKLE (clinicaltrialsregister.eu) - P2/3 | N=144 | Not yet recruiting | Sponsor: Centre Hospitalier Universitaire Rouen

New P2/3 trial • Anemia • Hematological Disorders • Sickle Cell Disease

AN AUDIT OF ILOPROST DELIVERY IN A TERTIARY SCLERODERMA SPECIALIST CENTRE (SSWC 2026) - "This included Iloprost indi- cation, frequency/duration of infusion and concomitant oral vasodilator therapy (including calcium channel antagonists, angiotensin receptor blockers, phosphodiesterase-5 inhibitors and bosentan). This data aligns with the 2024 BSR SSc guideline recommendation of the need for a dedicated day-case unit for Iloprost administration for a specific SSc patient cohort in addition to a severe PR/EM cohort. Optimisation of the Iloprost delivery pathway has potential to enhance better clinical outcomes and ensure more cost-efficiency."

Cardiovascular • Immunology • Scleroderma • Systemic Sclerosis

THE BURDEN OF CALCINOSIS CUTIS ON PERIPHERAL VASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS: DATA FROM THE ITALIAN SPRING REGISTRY (SSWC 2026) - "It also emerged that the presence of CC was associated with an increasing use of Iloprost (H 3.73, 95% CI: 1.35-10.36, p=0.011), but not of ERA, PDE5i or onset of new DU. Our data show that CC is related to a worsening of vascular involvement, particularly by increasing the need for treatment escalation. This result further supports the association between CC and vascular features of SSc, and suggests that CC might be considered as a clinical marker of a progressively severe vascular disease."

Cardiovascular • Immunology • Metabolic Disorders • Scleroderma • Systemic Sclerosis

MYCOPHENOLATE MOFETIL IN LIMITED SCLERODERMA REDUCES THE RISK OF VASCULAR COMPLICATION LEADING TO TREATMENT ESCALATION: EMULATION OF A TARGET TRIAL USING TIME-DEPENDENT PROPENSITY SCORE-MATCHING (SSWC 2026) - "The score was based on age, gender, disease duration, presence of anti-centromere antibodies and anti-Scl-70+ antibody, ILD, pulmonary function tests, history of digital ulcers, and baseline treatment with iloprost, calcium channel blockers, endothelin receptor antagonists (ERA), and phosphodiesterase-5 inhibitors (PDE5i). In the national SPRING cohort, the decision to prescribe MMF is primarily driven by the presence of risk factors for progressivE pulmonary manifestations. The association of MMF therapy with a reduced need for escalation of vasoactive or vasodila- tor treatment suggests a potential impact of this drug in preventing vascular complications in patients with lcSSc."

Fibrosis • Immunology • Interstitial Lung Disease • Myositis • Pulmonary Disease • Respiratory Diseases • Scleroderma • Systemic Sclerosis

A MICROCOSTING STUDY OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) BASED ON REAL WORLD DATA FROM BRAZIL (ISPOR 2026) - "OBJECTIVES: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease that has pulmonary endarterectomy (PEA) as the gold standard treatment, while ballon pulmonary angioplasty (BPA) and guanylate cyclase stimulator (riociguat) are recommended for patients who cannot undergo surgery or who relapse after PEA. Patients with CTEPH account for an excessive burden on the system. Strategies to reduce the impact of the disease should be pursued from both clinical and financial perspectives."

Clinical • Real-world • Real-world evidence • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Rare Diseases • Respiratory Diseases

Iloprost in Adults With Sepsis: Meta-Analysis of Randomized Controlled Trials (ATS 2026) - No abstract available

Retrospective data • Infectious Disease • Septic Shock

A study on the accessibility and utilisation of targeted drugs for pulmonary arterial hypertension in China. (PubMed, Front Pharmacol) - "Among all drugs, treprostinil had the highest availability (56.1% across hospitals), while newer drugs such as selexipag had very low availability (3,700 CNY)...Drug accessibility exhibited significant structural imbalances, with some drugs being "affordable but hard to obtain" (e.g., riociguat) and others "highly burdensome and poorly accessible" (e.g., treprostinil). The findings demonstrate significant improvements in the affordability and availability of PAH-targeted therapies over the study period; however, notable inequalities persist in accessibility improvements across urban and rural areas and income groups. Future policies should be tailored to address specific accessibility challenges for different drug categories and focus on overcoming medication access barriers for low-income rural populations to foster health equity."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

A treprostinil inhaler (Yutrepia) for pulmonary hypertension. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Sympatho-Excitation in Pulmonary Hypertension: The Potential Role of Pulmonary Arterial Baroreceptors: An Acute Physiologic Intervention Study. (PubMed, Respirology) - P | "These findings provide evidence suggestive of possible pulmonary arterial baroreceptor influence of MSNA burst amplitude in some PH patients. Pulmonary arterial baroreceptor activation may be a contributory mechanism to adverse sympatho-excitation in PH."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Strontium-doped hydroxyapatite microspheres loaded with iloprost promote dentin-pulp complex regeneration. (PubMed, Front Bioeng Biotechnol) - "Ilo@Sr-HA combines Sr2+ ionic cues with iloprost's pharmacological effects to form a bioactive microenvironment that supports pulp repair and reparative dentinogenesis. Ilo@Sr-HA is a promising material for VPT and dentin-pulp regeneration."

Journal • Inflammation

Insulin Resistance in Systemic Sclerosis: Decoding Its Association with Severe Clinical Phenotype. (PubMed, J Clin Med) - "Medications such as hydroxychloroquine, statins, and Iloprost were more frequently used in the IR group; as for corticosteroids usage (21.1% vs. 5.9%, p = 0.002), however, cumulative glucocorticoid dosage did not differ between the groups. In multivariable analysis, BMI (OR 1.09; p = 0.038) and interstitial lung disease (ILD) (OR 3.03; p = 0.034) were independent predictors of IR. In SSc, IR is associated with ILD, digital ulcers, musculoskeletal involvement, and anti-Scl70 autoantibodies."

Journal • Cardiovascular • Dyslipidemia • Immunology • Interstitial Lung Disease • Metabolic Disorders • Musculoskeletal Diseases • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

PROMISE: Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension (clinicaltrials.gov) - P=N/A | N=32 | Not yet recruiting | Sponsor: University of Sao Paulo General Hospital

New trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Iloprost, a Prostacyclin Analogue, Alleviates Oxidative Stress and Improves Development of Parthenogenetic Porcine Embryos via Nrf2/Keap1 Signaling. (PubMed, Antioxidants (Basel)) - "This study demonstrates that PGI2 protects embryos by activating Nrf2/Keap1 signaling, establishing this axis as a key antioxidant defense during embryonic development and highlighting its potential to improve embryo culture systems."

Journal • Preclinical

MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY. (PubMed, Arthritis Care Res (Hoboken)) - "In lcSSc patients, the introduction of MMF has reduced the need for escalation of vasoactive or vasodilator treatment, suggesting that it may also help to prevent vascular complications, which frequently affect patients with lcSSc."

Journal • Fibrosis • Immunology • Interstitial Lung Disease • Myositis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis • Transplantation